Marksans Pharma’s arm gets UK MHRA approval for Fluoxetine Oral Solution

Marksans Pharma Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 524404 | NSE: MARKSANS

23 Jan 2023 Evaluate

UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Market Authorisation to Marksans Pharma’s wholly owned subsidiary Relonchem for Fluoxetine 20mg/5ml Oral Solution.

Therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders. The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) located at Gifford House, Slaidburn Crescent, Southport, UK.

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.

Peers

Company Name	CMP
Sun Pharma. Inds.	1853.50
Dr. Reddys Labs.	1202.80
Cipla	1397.20
Lupin	2090.00
Zydus Lifesciences	1202.00
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.